Table 2.

Relative odds between FLI and HUA in different models among hypertensive patients in different sex.

FLI	Participants, n	Events, N (%)	HUA b , OR (95% CI) P-value
			Crude	Model 1	Model 2	Model 3
All participants
per SD increase	13716	6099 (44.5)	1.59 (1.53, 1.64) < 0.001	1.75 (1.68, 1.82) < 0.001	1.77 (1.69, 1.86) < 0.001	1.78 (1.69, 1.87) < 0.001
clinical cutoff
< 30	7720	2792 (36.2)	1	1	1	1
≥ 30	5996	3307 (55.2)	2.17 (2.03, 2.33) < 0.001	2.54 (2.36, 2.74) < 0.001	2.56 (2.34, 2.81) < 0.001	2.53 (2.30, 2.77) < 0.001
Quartile a
Q1 (< 10.4)	3429	1143 (33.3)	1	1	1	1
Q2 (10.4–24.7)	3429	1291 (37.6)	1.21 (1.09, 1.33) 0.0002	1.43 (1.29, 1.59) < 0.001	1.47 (1.30, 1.67) < 0.001	1.47 (1.30, 1.67) < 0.001
Q3 (24.7–48.7)	3429	1568 (45.7)	1.69 (1.53, 1.86) < 0.001	2.18 (1.96, 2.43) < 0.001	2.29 (2.01, 2.59) < 0.001	2.28 (2.01, 2.59) < 0.001
Q4 (≥ 48.7)	3429	2097 (61.2)	3.15 (2.85, 3.48) < 0.001	4.23 (3.79, 4.73) < 0.001	4.34 (3.80, 4.95) < 0.001	4.33 (3.78, 4.96) < 0.001
P for trend			< 0.001	< 0.001	< 0.001	< 0.001
Male
per SD increase	6478	3954 (64.8)	1.56 (1.48, 1.65) <0.001	1.68 (1.58, 1.78) <0.001	1.64 (1.53, 1.76) <0.001	1.70 (1.58, 1.83) < 0.001
clinical cutoff
< 30	3581	1906 (53.2)	1	1	1	1
≥ 30	2897	2048 (70.7)	2.12 (1.91, 2.35) < 0.001	2.28 (2.04, 2.54) < 0.001	2.14 (1.88, 2.45) < 0.001	2.22 (1.94, 2.55) < 0.001
Quartile
Q1 (< 10.4)	1695	827 (48.8)	1	1	1	1
Q2 (10.4–24.7)	1509	851 (56.4)	1.36 (1.18, 1.56) < 0.001	1.43 (1.24, 1.64) < 0.001	1.53 (1.29, 1.81) < 0.001	1.56 (1.31, 1.84) < 0.001
Q3 (24.7–48.7)	1521	951 (62.5)	1.75 (1.52, 2.02) < 0.001	1.94 (1.68, 2.25) < 0.001	1.98 (1.66, 2.36) < 0.001	2.04 (1.71, 2.44) < 0.001
Q4 (≥ 48.7)	1753	1325 (75.6)	3.25 (2.81, 3.76) < 0.001	3.83 (3.28, 4.49) < 0.001	3.73 (3.09, 4.51) < 0.001	4.04 (3.33, 4.91) < 0.001
P for trend			< 0.001	< 0.001	< 0.001	< 0.001
Female
per SD increase	7238	2145 (35.2)	1.69 (1.61, 1.79) < 0.001	1.80 (1.70, 1.90) < 0.001	1.89 (1.77, 2.02) < 0.001	1.85 (1.73, 1.98) < 0.001
clinical cutoff
< 30	4139	886 (21.4)	1	1	1	1
≥ 30	3099	1259 (40.6)	2.51 (2.27, 2.79) < 0.001	2.75 (2.47, 3.06) < 0.001	2.94 (2.60, 3.34) < 0.001	2.80 (2.46, 3.18) < 0.001
Quartile
Q1 (<10.4)	1734	316 (18.2)	1	1	1	1
Q2 (10.4–24.7)	1920	440 (22.9)	1.33 (1.13, 1.57) 0.0005	1.43 (1.22, 1.69) < 0.001	1.43 (1.18, 1.73) 0.0002	1.40 (1.16, 1.69) 0.0006
Q3 (24.7–48.7)	1908	617 (32.3)	2.14 (1.84, 2.50) < 0.001	2.41 (2.06, 2.82) < 0.001	2.58 (2.15, 3.10) < 0.001	2.48 (2.06, 2.99) < 0.001
Q4 (≥ 48.7)	1676	772 (46.1)	3.83 (3.28, 4.48) < 0.001	4.53 (3.86, 5.32) < 0.001	4.90 (4.05, 5.92) < 0.001	4.58 (3.77, 5.55) < 0.001
P for trend			< 0.001	< 0.001	<0.001	< 0.001
P for interactionc						0.0063

Crude was adjusted for none.

Model 1 was adjusted for age and sex (only for the overall population).

Model 2 was adjusted for age, sex (only for the overall population), BMI, WC, education, living standard, physical activity, current smoking, current drinking, Hcy, creatinine, and eGFR.

Model 3 was adjusted for age, sex (only for the overall population), BMI, WC, education, living standard, physical activity, current smoking, current drinking, Hcy, creatinine, eGFR, diabetes mellitus, antihypertensive drugs, glucose-lowering drugs.

FLI, Fatty Liver Index; HUA, hyperuricemia; CI, confidence interval

^aQuartile grouped according to the ranges of FLI value in quartile were Quartile1 (0.3-10.4), Quartile2 (10.4-24.7), Quartile3 (24.7-48.7), and Quartile4 (48.7-100.0), respectively.

^bHUA was defined as erum uric acid ≥ 360 μmol/L for females and ≥ 420 μmol/L for males.

^cTest for interaction between Fatty Liver Index (< 30 vs. ≥ 30) and HUA (yes or no) among hypertensive patients in different sex.